Table 1.
Characteristics of studies included in the meta-analysis
| Study | Year | Country | Ethnicity | Study design | Genotyping method | Source of control | Cancer type | Sample size (case/control) |
|---|---|---|---|---|---|---|---|---|
| Dai et al16 | 2014 | People’s Republic of China | Asian | CC | TaqMan | Population | EC | 2,083/2,220 |
| Wang et al17 | 2014 | People’s Republic of China | Asian | CC | TaqMan | Population | BC | 1,210/1,008 |
| Ma et al18 | 2013 | People’s Republic of China | Asian | CC | iPLEX | Population | BC | 184/962 |
| Zhao et al19 | 2013 | People’s Republic of China | Asian | CC | DHPLC | Population | GC | 717/951 |
| Rizzato et al20 | 2013 | Venezuela | Mixed | CC | TaqMan | Hospital | GC | 180/1,061 |
| Rai et al21 | 2013 | India | Asian | CC | TaqMan | Population | GBC | 405/247 |
| Ono et al22 | 2013 | Japan | Asian | CC | TaqMan | Hospital | GBC | 44/173 |
| Fu et al23 | 2012 | Europe | Caucasian | CC | TaqMan | Population | BC | 5,393/7,324 |
| Li et al24 | 2012 | People’s Republic of China | Asian | CC | iPLEX | Hospital | GC | 300/300 |
| Smith et al25 | 2012 | Scotland | Caucasian | CC | TaqMan | Hospital | CRC | 77/804 |
| Sala et al26 | 2012 | Europe | Caucasian | CC | SNP array | Population | GC | 411/1,530 |
| Zhao et al27 | 2012 | People’s Republic of China | Asian | CC | DHPLC | Population | GC | 185/200 |
| Tanikawa et al28 | 2012 | Japan | Asian | CC | SNP array | Hospital | GC | 2,300/16,567 |
| Song et al29 | 2011 | Korea | Asian | CC | PCR-RFLP | Hospital | GC | 3,245/1,700 |
| Zeng et al30 | 2011 | People’s Republic of China | Asian | CC | PCR-RFLP | Hospital | GC | 460/549 |
| Lochhead et al31a | 2011 | Poland | Caucasian | CC | TaqMan | Population | GC | 312/383 |
| Lochhead et al31b | 2011 | USA | Caucasian | CC | TaqMan | Population | Upper GIC | 468*/211 |
| Wang et al32 | 2010 | People’s Republic of China | Asian | CC | PCR-RFLP | Hospital | BC | 581/580 |
| Ou et al33 | 2010 | People’s Republic of China | Asian | CC | PCR/LDR | Hospital | GC | 196/246 |
| Lu et al34 | 2010 | People’s Republic of China | Asian | CC | PCR-RFLP | Population | GC | 1,053/1,100 |
| Chen et al35 | 2010 | People’s Republic of China | Asian | CC | PCR-RFLP | Hospital | GC | 460/549 |
| Wu et al36 | 2009 | Europe | Caucasian | CC | TaqMan | Population | BC | 5,038/9,363 |
| Matsuo et al37 | 2009 | Japan | Asian | CC | TaqMan | Hospital | GC | 708/708 |
| Wu et al38 | 2009 | People’s Republic of China | Asian | CC | PCR-RFLP | Population | GC | 1,736/1,020 |
| Sakamoto et al9a | 2008 | Japan | Asian | CC | TaqMan | Population | GC | 1,531/1,399 |
| Sakamoto et al9b | 2008 | Korea | Asian | CC | TaqMan | Population | GC | 871/390 |
Notes:
Including 309 gastric cancer cases and 159 esophageal cancer cases. Lochhead et al31a refers the study evaluated association of the rs2294008 polymorphism with gastric cancer risk and Lochhead et al31b refers to the study evaluated association of the rs2294008 polymorphism with upper GI cancer risk. Sakamoto et al9a refers to the study evaluated association of the rs2294008 with gastric cancer types in Japan and Sakamoto et al9b refers to the study evaluated association of the rs2294008 with gastric cancer types in Korea.
Abbreviations: BC, bladder cancer; CC, case–control; CRC, colorectal cancer; DHPLC, denaturing high-performance liquid chromatography; EC, esophageal cancer; GBC, gallbladder cancer; GIC, gastrointestinal cancers; GC, gastric cancer; LDR, ligation detection reaction; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SNP, single nucleotide polymorphism.